Adverse reactions seen at lower rates but at about the same or greater incidence as in patients receiving placebo included hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia.
In individual clinical trials of amlodipine and olmesartan medoxomil, other commonly reported adverse reactions included headache, dizziness, and flushing.
For more information on AZOR, call 877-4-DSPROD (877-437-7763) or go to the web site http://www.azor.com.
About Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the
U.S. subsidiary of Daiichi Sankyo Co., Ltd., Japan's second largest
pharmaceutical company and a global leader in pharmaceutical innovation
since 1899. The company is dedicated to the discovery, development and
commercialization of innovative medicines that improve the lives of
patients throughout the world. The primary focus of Daiichi Sankyo's
research and development is cardiovascular disease, including therapies for
dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The
company is also pursuing the discovery of new medicines in the areas of
glucose metabolic disorders, infectious diseases, cancer, bone and joint
diseases, and immune disorders.
For more information, please visit http://www.dsus.com.
* SeDBP = Seated Diastolic Blood Pressure. According to the JNC 7, a
SeDBP between 90 and 99 is considered stage 1 hypertension and 100
and above is considered stage 2 hypertension.
(1) Ong KL, et al. Prevalence, awareness, treatment and control of
hypertension among United States Adults 1999-2004. Hypertens 2007;
(2) Margolis et al. Blood Pressure Control
|SOURCE Daiichi Sankyo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved